COVID-19 - February 16, 2021
AstraZeneca’s vaccine authorized for emergency use by the WHO
AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals 18 years of age and older, including those over 65. The authorization of COVID-19 Vaccine AstraZeneca manufactured by AstraZeneca, and COVISHIELD manufactured by Serum Institute of India (SII), enables global access […]
COVID-19 - February 10, 2021
First clinical trials of Sputnik V and COVID-19 Vaccine AstraZeneca
The Ministry of Healthcare of Republic of Azerbaijan granted an approval to conduct clinical trials of the combined use of the Sputnik V and the COVID 19 vaccine AstraZeneca in Azerbaijan. Previously, the Gamaleya National Center, RDIF, AstraZeneca and R-Pharm signed an agreement to cooperate on COVID-19 vaccine development, which was announced in December 2020. The trial will […]
COVID-19 - February 10, 2021
AstraZeneca & IDT Biologika sign letter of intent to increase vaccine manufacturing
AstraZeneca and IDT Biologika are exploring options to accelerate output of finished COVID-19 Vaccine AstraZeneca in the second quarter of 2021. AstraZeneca and IDT Biologika also intend to strengthen Europe’s vaccine manufacturing capability with a joint investment to build large additional drug substance capacity for the future. Details of the agreement are to be finalized. […]
Acquisition - February 3, 2021
AstraZeneca to divest Viela shareholding
AstraZeneca has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio, Inc., as part of the proposed acquisition of Viela by Horizon Therapeutics. AstraZeneca is anticipating to receive cash proceeds and profit of c.$760-$780m upon closing for the sale of the holding, which will be recorded in Reported and Core […]
COVID-19 - January 31, 2021
AstraZeneca’s COVID-19 vaccine authorized for use in the EU
AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorization (CMA) in the European Union (EU) for active immunization to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Following review of the application, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive […]
Pharma Business - January 28, 2021
AstraZeneca’s Symbicort Turbuhaler approved in China
AstraZeneca’s Symbicort Turbuhaler has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve asthma control in patients with mild asthma aged 12 years and older. The approval by the National Medical Products Administration (NMPA) was based on positive results from the SYGMA 1 and SYGMA 2 […]
